NorthWest Biotherapeutics Inc (NWBO)

[Gus1212]

FDA Approves Trial
FDA Allows Ziopharm's Brain Cancer Drug Trial


The Boston, Massachusetts-based biopharmaceutical company will now proceed with planning registration for the trial, which will be initiated in 2017.

The planning will finalize the protocol design options for the trial, which will include a comparative assessment of the drug against historical controls in a subset of recurrent GBM patients. Recurrence indicates return of a sign, symptom, or disease after a period of disappearance. The company will share the details of the Phase 3 trial in the near future once the discussions are finalized with clinical advisors as well as regulators.

Glioblastoma is a malignant tumor that affects the brain or spine. The cancer spreads rapidly, and leads to headache, nausea, drowsiness, blurred vision, personality changes and seizures. (See also, Tracon Tanks on Brain Cancer Drug Failure.)

A lot of drugs are being developed by different companies for treating glioblastoma. They include Northwest Biotherapeutics Inc.’s (NWBO
Northwest Biotherapeutics Inc
NWBO
0.16
-3.57%
) DCVax-L, GW Pharmaceuticals PLC’s (GWPH
GW Pharmaceuticals Shs Sponsored American Deposit Share Repr 12 Shs
GWPH
103.73
-2.15%
) combination therapy of cannabidiol and tetrahydrocannabinol, and Agenus Inc.'s (AGEN
Agenus Inc
AGEN
3.74
-1.58%
) Prophage (HSPPC-96) in combination with Merck & Co. Inc.'s (MRK
Merck & Co Inc
MRK
64.43
+0.77%
) Keytruda (pembrolizumab). (See also, GW Pharma Spikes on Cannabis Drug Success.)



Read more: FDA Allows Ziopharm Brain Cancer Drug Trial (ZIOP) | Investopedia http://www.investopedia.com/news/fda-allows-ziopharm-brain-cancer-drug-trial-ziop/#ixzz4grtbqphf
Follow us: Investopedia on Facebook